Search
for
Sort by
Research
540-570 / 1000+ results
research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
research Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy
Sintilimab treatment caused hair loss but led to complete tumor remission.
research Lysocellin, a metabolite of the novel drug ‘alopestatin’, induces G1 arrest and prevents cytotoxicity induced by etoposide
Lysocellin helps stop cell damage from etoposide and may prevent hair loss.
research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
research PROTACs: A novel strategy for cancer drug discovery and development
PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
research Characteristics and predictive values of super-responders in alopecia areata under tofacitinib treatment: A single-center retrospective study
Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
research Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects
Vismodegib is effective for basal cell carcinoma but has severe side effects.
research Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies
The herbal combination of saw palmetto and stinging nettle reduces nighttime urination in men with urinary issues.
research Editorial Comment
5-ARI therapy may help prevent prostate cancer progression.
research Towards a consensus potency assay for mesenchymal stromal cells: a matrix analysis of cell source, donor variability and inflammatory stimuli to refine surrogate markers of immunomodulation
ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.
research Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
research 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata
Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
research Oral tofacitinib for the treatment of alopecia areata in pediatric patients
Tofacitinib taken by mouth helps treat hair loss in children.
research Refractory/relapse thrombocytopenia in a patient with Evans' syndrome successfully treated with zanubrutinib
A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
research Baricitinib in Alopecia Areata
Baricitinib is not very effective for severe alopecia areata.
research TOFACITINIB IN OVERLAPPING AUTOIMMUNE AND AUTOINFLAMMATORY DISORDERS: A CASE REPORT OF A DUAL GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME AND HIDRADENITIS SUPPURATIVA
Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
research Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Tyrosine kinase inhibition and grey hair
Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
research TNF ‐inhibitor associated psoriatic alopecia: Diagnostic utility of sebaceous lobule atrophy
Shrinking of oil glands in the skin is a key sign of hair loss linked to TNF inhibitor drugs and may improve if the treatment is stopped.
research Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients
research Reversal of Alopecia Universalis by Tofacitinib: A Case Report
Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
research Natural Product-InspiredBis(trifluoromethyl) PhenylHydroxycinnamate Derivatives as Promising Nonsteroidal Inhibitorsof Human Steroid 5α-Reductase Type-1: Synthesis, InVitro, and In Silico Studies
Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.
research Adverse Effects and Drug Interactions of Biologic Agents
Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
research Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata
A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
research Recalcitrant lichen planopilaris treated with upadacitinib: a case series
Upadacitinib may effectively treat resistant lichen planopilaris.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses After 24 and 48 Weeks of Treatment With Ritlecitinib
research Management of Toxicities of Targeted Therapies
Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.